JÃ¼rgen K J Schwarze

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5697817/publications.pdf

Version: 2024-02-01

105 papers	6,581 citations	50276 46 h-index	66911 78 g-index
110 all docs	110 docs citations	110 times ranked	8631 citing authors

#	Article	IF	Citations
1	Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. EBioMedicine, 2022, 76, 103856.	6.1	38
2	Effects of nonâ€steroidal antiâ€inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2337-2354.	5.7	9
3	Hypoxia shapes the immune landscape in lung injury and promotes the persistence of inflammation. Nature Immunology, 2022, 23, 927-939.	14.5	21
4	Spotlight on microRNAs in allergy and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1661-1678.	5.7	98
5	EAACI Biologicals Guidelinesâ€"Recommendations for severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 14-44.	5.7	156
6	COVIDâ€19 pandemic: Practical considerations on the organization of an allergy clinicâ€"An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	5.7	79
7	ARIAâ€EAACI statement on asthma and COVIDâ€19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
8	Efficacy and safety of dupilumab for moderateâ€toâ€severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 45-58.	5.7	41
9	Prostaglandin E ₂ promotes intestinal inflammation via inhibiting microbiota-dependent regulatory T cells. Science Advances, 2021, 7, .	10.3	44
10	Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2337-2353.	5.7	78
11	ARIAâ€EAACI care pathways for allergen immunotherapy in respiratory allergy. Clinical and Translational Allergy, 2021, 11, e12014.	3.2	24
12	ARIAâ€EAACI statement on severe allergic reactions to COVIDâ€19 vaccines â€“ An EAACIâ€ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1624-1628.	5.7	66
13	Impact of clinical and patient pathway changes on paediatric research during the national COVID-19 response. Archives of Disease in Childhood, 2021, 106, archdischild-2021-322865.	1.9	0
14	COVIDâ€19 pandemic and allergen immunotherapyâ€"an EAACI survey. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3504-3516.	5.7	26
15	EAACI Biologicals Guidelinesâ€"dupilumab for children and adults with moderateâ€toâ€severe atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 988-1009.	5.7	24
16	Effectiveness of mobile health interventions to improve nasal corticosteroid adherence in allergic rhinitis: A systematic review. Clinical and Translational Allergy, 2021, 11, e12075.	3.2	6
17	Seasonal Influenza Vaccine Effectiveness in People With Asthma: A National Test-Negative Design Case-Control Study. Clinical Infectious Diseases, 2020, 71, e94-e104.	5.8	10
18	Preschool wheezing diagnosis and managementâ€"Survey of physiciansâ€™ and caregiversâ€™ perspective. Pediatric Allergy and Immunology, 2020, 31, 206-209.	2.6	8

#	Article	IF	Citations
19	A compendium answering 150 questions on COVIDâ€19 and SARSâ€CoVâ€2. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2503-2541.	5.7	95
20	Correspondence to â€œBronchiolitis needs a revisit: Distinguishing between virus entities and their treatmentsâ€• Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1529-1530.	5.7	0
21	Comparative primary paediatric nasal epithelial cell culture differentiation and RSV-induced cytopathogenesis following culture in two commercial media. PLoS ONE, 2020, 15, e0228229.	2.5	14
22	Intranasal corticosteroids in allergic rhinitis in COVIDâ€19 infected patients: An ARIAâ€EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2440-2444.	5.7	114
23	Immunology of COVIDâ€19: Mechanisms, clinical outcome, diagnostics, and perspectivesâ€”A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2445-2476.	5.7	132
24	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) Tj ETQq0 0 0 rgBT /Overlock 10 recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1023-1042.	5.7	232
25	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines â€recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1043-1057.	5.7	85
26	EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1899-1901.	5.7	3
27	Handling of allergen immunotherapy in the COVIDâ€19 pandemic: An ARIAâ€EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1546-1554.	5.7	87
28	Impact of preterm birth on brain development and long-term outcome: protocol for a cohort study in Scotland. BMJ Open, 2020, 10, e035854.	1.9	34
29	Mcl-1 protects eosinophils from apoptosis and exacerbates allergic airway inflammation. Thorax, 2020, 75, 600-605.	5.6	8
30	Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study. Health Technology Assessment, 2020, 24, 1-66.	2.8	5
31	Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. Allergologie Select, 2020, 4, 53-68.	3.1	38
32	Title is missing!. , 2020, 15, e0228229.		0
33	Title is missing!. , 2020, 15, e0228229.		0
34	Title is missing!. , 2020, 15, e0228229.		0
35	Title is missing!. , 2020, 15, e0228229.		0
36	Lung eosinophilsâ€”A novel â€œvirus sinkâ€•that is defective in asthma?. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1832-1834.	5.7	15

#	Article	IF	Citations
37	Development and implementation of a nurse-led allergy clinic model in primary care: feasibility trial protocol. Npj Primary Care Respiratory Medicine, 2019, 29, 44.	2.6	1
38	Bronchiolitis needs a revisit: Distinguishing between virus entities and their treatments. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 40-52.	5.7	103
39	Expression of the B cell differentiation factor BAFF and chemokine CXCL13 in a murine model of Respiratory Syncytial Virus infection. Cytokine, 2018, 110, 267-271.	3.2	14
40	Mer-mediated eosinophil efferocytosis regulates resolution of allergic airway inflammation. Journal of Allergy and Clinical Immunology, 2018, 142, 1884-1893.e6.	2.9	28
41	Pulmonary epithelial barrier and immunological functions at birth and in early life - key determinants of the development of asthma?Â A description of the protocol for the Breathing Together study. Wellcome Open Research, 2018, 3, 60.	1.8	14
42	Differential lower airway dendritic cell patterns may reveal distinct endotypes of RSV bronchiolitis. Thorax, 2017, 72, 620-627.	5.6	46
43	The Human Immune Response to Respiratory Syncytial Virus Infection. Clinical Microbiology Reviews, 2017, 30, 481-502.	13.6	264
44	Enteric helminth-induced type I interferon signaling protects against pulmonary virus infection through interaction with the microbiota. Journal of Allergy and Clinical Immunology, 2017, 140, 1068-1078.e6.	2.9	93
45	Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. BMJ Open, 2017, 7, e014200.	1.9	12
46	Broad-Spectrum Inhibition of Respiratory Virus Infection by MicroRNA Mimics Targeting p38 MAPK Signaling. Molecular Therapy - Nucleic Acids, 2017, 7, 256-266.	5.1	56
47	Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2017, 65, 1388-1395.	5.8	99
48	Nitric oxide induces human CLA + CD25 + Foxp3 + regulatory T cells with skin-homing potential. Journal of Allergy and Clinical Immunology, 2017, 140, 1441-1444.e6.	2.9	17
49	HpARI Protein Secreted by a Helminth Parasite Suppresses Interleukin-33. Immunity, 2017, 47, 739-751.e5.	14.3	130
50	Vaccination and allergy: <scp>EAACI</scp> position paper, practical aspects. Pediatric Allergy and Immunology, 2017, 28, 628-640.	2.6	103
51	Pediatric Pulmonologyyear in review 2015: Part 1. Pediatric Pulmonology, 2016, 51, 733-739.	2.0	3
52	Viral mimic poly-(I:C) attenuates airway epithelial T-cell suppressive capacity: implications for asthma. European Respiratory Journal, 2016, 48, 1785-1788.	6.7	11
53	Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans. Journal of Immunology, 2016, 196, 2699-2710.	0.8	129
54	Microbes and asthma: Opportunities for intervention. Journal of Allergy and Clinical Immunology, 2016, 137, 690-697.	2.9	68

#	Article	IF	Citations
55	Pediatric pulmonology year in review 2014: Part 2. Pediatric Pulmonology, 2015, 50, 1140-1146.	2.0	0
56	Wogonin Induces Eosinophil Apoptosis and Attenuates Allergic Airway Inflammation. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 626-636.	5.6	62
57	Effector and central memory T helper 2 cells respond differently to peptide immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E784-E793.	7.1	21
58	Viral respiratory tract infections and asthma in early life: cause and effect?. Clinical and Experimental Allergy, 2014, 44, 9-19.	2.9	16
59	The role of proâ€resolution lipid mediators in infectious disease. Immunology, 2014, 141, 166-173.	4.4	103
60	Chest auscultatory signs in infants presenting to A&E with bronchiolitis. European Journal of Emergency Medicine, 2014, 21, 436-441.	1.1	2
61	Novel insights into immune and inflammatory responses to respiratory viruses. Thorax, 2013, 68, 108-110.	5.6	26
62	Republished: Novel insights into immune and inflammatory responses to respiratory viruses. Postgraduate Medical Journal, 2013, 89, 516-518.	1.8	1
63	Combination peptide immunotherapy based on <scp>T</scp>â€cell epitope mapping reduces allergenâ€specific <scp>I</scp>g<scp>E</scp> and eosinophilia in allergic airway inflammation. Immunology, 2013, 138, 258-268.	4.4	27
64	The Human Cathelicidin LL-37 Has Antiviral Activity against Respiratory Syncytial Virus. PLoS ONE, 2013, 8, e73659.	2.5	157
65	OX40 Ligand and Programmed Cell Death 1 Ligand 2 Expression on Inflammatory Dendritic Cells Regulates CD4 T Cell Cytokine Production in the Lung during Viral Disease. Journal of Immunology, 2012, 188, 1647-1655.	0.8	14
66	Respiratory and gastrointestinal epithelial modulation of the immune response during viral infection. Innate Immunity, 2012, 18, 179-189.	2.4	11
67	Lymphoid and myeloid cell populations in the non-pregnant human Fallopian tube and in ectopic pregnancy. Journal of Reproductive Immunology, 2011, 89, 84-91.	1.9	24
68	Neosensitization to Allergens after Resolution of Allergic Airways Inflammation. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 283-284.	5.6	2
69	Peptide immunotherapy for childhood allergy â€•addressing translational challenges. Clinical and Translational Allergy, 2011, 1, 13.	3.2	5
70	Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 382-395.	1.9	102
71	Mechanisms at the Interface of Innate and Adaptive Immunity in the Pathogenesis of RSV Disease: Lessons from the Mouse Model. Current Respiratory Medicine Reviews, 2011, 7, 176-182.	0.2	0
72	Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset. Expert Review of Molecular Diagnostics, 2011, 11, 197-206.	3.1	16

#	Article	IF	Citations
73	Respiratory Viral Infections in Infants: Causes, Clinical Symptoms, Virology, and Immunology. Clinical Microbiology Reviews, 2010, 23, 74-98.	13.6	590
74	CD25 ⁺ Natural Regulatory T Cells Are Critical in Limiting Innate and Adaptive Immunity and Resolving Disease following Respiratory Syncytial Virus Infection. Journal of Virology, 2010, 84, 8790-8798.	3.4	133
75	The Chemokine MIP1Î±/CCL3 Determines Pathology in Primary RSV Infection by Regulating the Balance of T Cell Populations in the Murine Lung. PLoS ONE, 2010, 5, e9381.	2.5	51
76	Healthy but not RSV-infected lung epithelial cells profoundly inhibit T cell activation. Thorax, 2009, 64, 283-290.	5.6	36
77	Prostaglandin F2Î±-F-Prostanoid Receptor Signaling Promotes Neutrophil Chemotaxis via Chemokine (C-X-C Motif) Ligand 1 in Endometrial Adenocarcinoma. Cancer Research, 2009, 69, 5726-5733.	0.9	45
78	Molecular and cellular mechanisms in the viral exacerbation of asthma. Microbes and Infection, 2008, 10, 1014-1023.	1.9	15
79	Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nature Medicine, 2008, 14, 199-204.	30.7	339
80	Respiratory syncytial virus infection provokes airway remodelling in allergenâ€exposed mice in absence of prior allergen sensitization. Clinical and Experimental Allergy, 2008, 38, 1016-1024.	2.9	51
81	Respiratory syncytial virus infection provokes airway remodelling in allergen-exposed mice in absence of prior allergen sensitization. Clinical and Experimental Allergy, 2008, 38, 1241-1241.	2.9	0
82	Alveolar Macrophages Are a Major Determinant of Early Responses to Viral Lung Infection but Do Not Influence Subsequent Disease Development. Journal of Virology, 2008, 82, 4441-4448.	3.4	185
83	Lung Dendritic Cells in Respiratory Syncytial Virus Bronchiolitis. Pediatric Infectious Disease Journal, 2008, 27, S89-S91.	2.0	15
84	Reduced Lung Function in a Chronic Asthma Model Is Associated with Prolonged Inflammation, but Independent of Peribronchial Fibrosis. PLoS ONE, 2008, 3, e1575.	2.5	16
85	Plasmacytoid Dendritic Cells Limit Viral Replication, Pulmonary Inflammation, and Airway Hyperresponsiveness in Respiratory Syncytial Virus Infection. Journal of Immunology, 2006, 177, 6263-6270.	0.8	134
86	Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections?. Microbes and Infection, 2006, 8, 285-293.	1.9	31
87	Local CD11c+MHC Class IIâ^'Precursors Generate Lung Dendritic Cells during Respiratory Viral Infection, but Are Depleted in the Process. Journal of Immunology, 2006, 177, 2536-2542.	0.8	49
88	Inhalation of stable dust extract prevents allergen induced airway inflammation and hyperresponsiveness. Thorax, 2006, 61, 134-139.	5.6	69
89	Barometric whole body plethysmography in mice. Journal of Applied Physiology, 2005, 98, 1955-1957.	2.5	21
90	The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Respiratory Research, 2005, 6, 70.	3.6	51

#	Article	IF	Citations
91	Enhanced virulence, airway inflammation and impaired lung function induced by respiratory syncytial virus deficient in secreted G protein. Thorax, 2004, 59, 517-521.	5.6	23
92	Unravelling synergistic immune interactions between respiratory virus infections and allergic airway inflammation. Clinical and Experimental Allergy, 2004, 34, 1153-1155.	2.9	6
93	Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infectionâ˜†. Journal of Allergy and Clinical Immunology, 2004, 113, 127-133.	2.9	106
94	Latency and Persistence of Respiratory Syncytial Virus Despite T Cell Immunity. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 801-805.	5.6	143
95	Respiratory viral infections as promoters of allergic sensitization and asthma in animal models. European Respiratory Journal, 2002, 19, 341-349.	6.7	60
96	Die Rolle von Virusinfektionen der Atemwege bei Entstehung und Verlauf von asthma bronchiale im Kindesalter. Monatsschrift Fur Kinderheilkunde, 2001, 149, 120-128.	0.1	1
97	Critical Roles for Interleukin-4 and Interleukin-5 during Respiratory Syncytial Virus Infection in the Development of Airway Hyperresponsiveness after Airway Sensitization. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 380-386.	5.6	81
98	THE ROLE OF VIRUSES IN DEVELOPMENT OR EXACERBATION OF ATOPIC ASTHMA. Clinics in Chest Medicine, 2000, 21, 279-287.	2.1	15
99	Development of Eosinophilic Airway Inflammation and Airway Hyperresponsiveness Requires Interleukin-5 but Not Immunoglobulin E or B Lymphocytes. American Journal of Respiratory Cell and Molecular Biology, 1999, 21, 480-489.	2.9	152
100	Negative regulation of airway responsiveness that is dependent on Î³Î´ T cells and independent of Î±Î² T cells. Nature Medicine, 1999, 5, 1150-1156.	30.7	166
101	Systemic and Local Interferon gamma Gene Delivery to the Lungs for Treatment of Allergen-Induced Airway Hyperresponsiveness in Mice. Human Gene Therapy, 1999, 10, 1905-1914.	2.7	85
102	Anti-interleukin 5 But Not Anti-IgE Prevents Airway Inflammation and Airway Hyperresponsiveness. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 934-941.	5.6	138
103	The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. Journal of Clinical Investigation, 1999, 104, 301-308.	8.2	175
104	Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice. Journal of Allergy and Clinical Immunology, 1998, 102, 86-93.	2.9	94
105	Antigen-specific Immunoglobulin-A Prevents Increased Airway Responsiveness and Lung Eosinophilia after Airway Challenge in Sensitized Mice. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 519-525.	5.6	57